摘要
目的采用低剂量环磷酰胺（CTX）联合人参皂甙Rg3治疗晚期非小细胞肺癌，观察其临床疗效及毒副作用。方法对化疔后的晚期（Ⅲ、Ⅳ期）非小细胞肺癌（NSCLC）患者进行临床随机研究，治疗组（38例）：CTX 50mg每日一次联合参一胶囊20mg每日两次口服，3～6个月；对照组（34例）：化疗后不用任何药物治疗。结果联合治疗组患者外周血血管内皮生长因子（VEGF）表达下降，T淋巴细胞亚群CD4^＋及CD4^＋／CD8^＋升高，病人生存质量及生存期提高。结论晚期NSCLC患者化疗后联合应用低剂量CTX联合人参皂甙Rg3是一种新的安全有效的治疗方法，可以提高患者的生存质量及生存期。
Objective The combination of low- dose cyclophosphamide（CTX） and giusenoside Rg3 was used to investigate its toxicity and efficacy in treating advanced non- small cell lung cancer patients. Methods Eligible patients had stage Ⅲ/Ⅳ disease, adequate hematology and biochemistry, and had been treated previously with 4 cycles chemotherapy. They were randomized into two groups. The therapeutic group was treated by CTX 50 mg qd pe plus ginsenoside Rg3 20 mg bid pe. The control group did not receive any treatment. Results The serum VEGF is low and CD4^＋ , CD4^＋/CD8^＋ cells is high in therapeutic group. The quality of life and survival of the patients were also raised in therapeutic group. Conclusion This experiment suggests a new safe therapeutic anticancer paradigm for controlling lung cancer, which will improve living quality of patient with cancer and prolong their survival.
出处
《实用肿瘤学杂志》
CAS
2006年第1期18-20,共3页
Practical Oncology Journal
